ANI Pharmaceuticals, Inc. ANIP
Updated: 17 Jun 2026
No signal published yet
We already track ANI Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow ANI Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow ANI Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 8, 2026, ANI Pharmaceuticals reported first-quarter financial results with revenue of $237.5 million, a 20% year-over-year increase driven by its Rare Disease and Generics segments. Following these results, the company raised its full-year 2026 revenue guidance to a range of $1.08 billion to $1.14 billion. Additionally, the board authorized a new $100 million share repurchase program in May 2026.
What Firelda Watch includes for ANI Pharmaceuticals, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow ANI Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow ANI Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more